North America Human Insulin Market Size, Share & Trends Analysis Report by Indication, Product Type (Pens, Syringes, and Others), Type of Insulin, Distribution Channel, Country and Growth Forecast, 2024-2031

The North America Human Insulin Market is projected to witness market growth of 2.7% CAGR during the forecast period (2024-2031).

The US market dominated the North America Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $5.04 billion by 2031. The Canada market is experiencing a CAGR of 4.9% during 2024-2031. Additionally, the Mexico market would exhibit a CAGR of 4% during 2024-2031.



Diabetes is a chronic disorder that affects millions of individuals. Since the discovery of insulin, the market for insulin has undergone substantial development, and it now plays an essential part in the management of diabetes. The need for effective diabetes treatments has increased in tandem with the increasing prevalence of diabetes, which is influenced by factors such as elderly populations, unhealthy diets, and sedentary lifestyles. Particularly for patients with type 1 diabetes and those with advanced type 2 diabetes, insulin, a hormone that is indispensable for managing blood glucose levels, continues to be a fundamental component of diabetes treatment.

The growing number of people who are diagnosed with diabetes is one of the key factors that is driving market expansion. This concerning trend emphasizes the pressing necessity for insulin-based diabetes management solutions. The prevalence of diabetes is not exclusively prevalent in high-income countries; it is also increasing at a rapid pace in low- and middle-income countries, where healthcare systems frequently encounter difficulties in managing the burden of chronic diseases.

Public health initiatives focused on diabetes prevention and management further support market growth in North America. Programs like the National Diabetes Prevention Program (NDPP) in the United States aim to reduce the incidence of type 2 diabetes through lifestyle interventions and education. In Canada, the Diabetes 360° initiative advocates for a national diabetes strategy to improve prevention, care, and outcomes for diabetic patients. These initiatives raise awareness about diabetes, promote early detection, and encourage adherence to treatment regimens, increasing the demand for insulin. Therefore, the region presents lucrative growth opportunities for the market in the coming years.

Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• MannKind Corporation
• Lupin Limited
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly And Company
• Medtronic PLC
• Biocon Limited
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Pfizer, Inc.

Market Report Segmentation

By Indication

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Product Type

• Pens
• Syringes
• Others

By Type of Insulin

• Rapid-acting insulin
• Short-acting insulin
• Intermediate-acting insulin
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Country

• US
• Canada
• Mexico
• Rest of North America